Quick facts
- Classification
- Synthetic peptide fragment of thymosin beta-4
- Target / mechanism
- Actin-binding and cell-migration pathways (proposed)
- Development status
- Preclinical; limited early-phase work on related full-length peptide
- Regulatory status
- Research use only
- Evidence level
- Preclinical only
- Therapeutic area
- Musculoskeletal / wound repair (proposed)
- Route / formulation
- Injectable preparations are marketed; none are approved
Also referred to as · Thymosin beta-4 fragment
What it is
TB-500 refers to a marketed synthetic fragment associated with thymosin beta-4, a naturally occurring actin-sequestering protein. TB-500 and thymosin beta-4 are not interchangeable in the evidence base.
How it works
Thymosin beta-4 is involved in actin regulation, cell migration, and angiogenesis in laboratory models. Whether the marketed fragment reproduces those effects at doses used outside research is not established.
What it has been studied for
- Wound healing and corneal repair models (mostly the full-length peptide)
- Cardiac and soft-tissue repair in animal models
Safety and side effects
No robust human safety data set exists for TB-500 as marketed. Product quality is a distinct and significant unknown.
Warnings and contraindications
Compounded / research status
Investigational uses
Some clinical work exists on full-length thymosin beta-4 in ophthalmic and dermatologic indications; that literature should not be read as evidence for marketed TB-500 products.
Frequently asked questions
References
- WADA Prohibited ListWorld Anti-Doping Agency
- Thymosin beta-4 preclinical literaturePeer-reviewed scientific literature
Reference entries are editorial placeholders describing source type and origin. Primary documents are linked as each profile is expanded.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.